Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
White Cliff Minerals identifies thick cobalt and nickel intervals at Coronation Dam

2018-07-06 proactiveinvestors.com.au
White Cliff Minerals Ltd (ASX:WCN) has identified thick cobalt and nickel intervals while logging core from drilling at the Coronation Dam Cobalt-Nickel Project in Western Australia.
GME WCN

7
Top 6 Cobalt Junior Developer Miners To Boom By 2021/2022

2018-05-17 seekingalpha
Six cobalt junior developers can each produce ~5,000 tonnes pa of cobalt by 2021/22. These companies each have the potential to be worth ~AUD 3b if cobalt prices remain strong.
CLA CCZ HAV GLCNF ECSIF CZI AMSLF BPLNF POS HIG AUZ RNX RNKLF GME AQR FT PSDNF AYR AEOMF KATFF RNX.WT FTMDF KAT CNJ BPL HLPCF CSSQF

0
White Cliff Minerals focuses on cobalt projects, maximising value while commodity price soars

2018-05-10 proactiveinvestors.com.au
White Cliff Minerals Ltd (ASX: WCN) has started reverse circulation drilling at its Coronation Dam cobalt project near Kookynie in Western Australia’s north-eastern Goldfields.
GME WCN

208
Cobalt Miners News For The Month Of March 2018

2018-03-25 seekingalpha
Cobalt spot price news - Spot prices rise 18.7% in the past month as inventory falls. The cobalt spot price is now over USD 40/lb, and approaching USD 100,000/tonne.
SIE PIO PANRF HAV PAN KBGCF MCR FCX ECSIF IGO VIC BAR AOU HIG PLM.RT TAKRF UMICF SNNAF FQM LGI MCRZF BXTMF MLX PSDNF POM CDU RGARF CHK VLKAF MCRZY FTMDF KAT RER CSSQF GMRSF CZN PGM GBLEF NZRIF AZS GLCNF DLE HBNRF MEI PIONF CZI AMSLF HMI POS AUZ RNX GME AAPL FQVLF AQR MBL PTNUF FT HNLMF ORR CDNMD 3993 UMICY CDNMF IIDDY AEOMF USCFF KATFF MLXEF OZMLF PLM S CNJ AZRMF HLPCF BHP OZL ARV

5
Australia Mines Offers Nickel-Cobalt Exposure With Three Promising Projects In Australia

2018-03-21 seekingalpha
The Sconi resource estimate has 54,500 tonnes of contained cobalt with exploration upside. The Sconi project has recently secured 100% cobalt and nickel off-take.
FT PSDNF HAV ECSIF AEOMF CZI AMSLF KATFF POS HIG AUZ RNX FTMDF KAT GME CNJ HLPCF CSSQF AQR GMRSF

0
White Cliff Minerals adopts dual strategy for cobalt-nickel and gold projects

2018-03-20 proactiveinvestors.com.au
White Cliff Minerals Ltd (ASX:WCN) has adopted a dual strategy focused on advancing its Western Australian cobalt-nickel projects at the same time as its Kyrgyz Republic gold project.
GME WCN

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ASX:GME / GME RESOURCES LIMITED on message board site Silicon Investor.

Fragments of Interest GameStop Corp (GME)
Judgment from Above? Microsoft: The Devices and Consumer Segment
GMED - GenoMed Inc. U.S. Microbics {BUGS} - Environmental Augmentation
SCRM: ScreamingMedia.com WHY DID THE BROKER SELL THE DOGMEAT?
DSGX E-Business- web-based supply chain managment Biogan Intl (BIGM or BIGME?)